Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-02 08:18:42 - browse：5778

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Phenylephrine and the overlooked value of the placebo effect

WSS

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Sana to lay off nearly a third of staff, de

Commercial surrogacy can be ethical, despite pope’s claims

Liquid biopsy for lung cancer is launched by Delfi

3 questions for the future of Biden's cancer moonshot

A virus, fished out of a lake, may have saved a man’s life

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

AI can decode, harness the power of the humane immune system

As demand for Covid shots wanes, Moderna seeks its next success

Even great ERs can’t make up for American health disparities

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Heart attack and stroke risk calculators need revising

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Drug repurposing or repositioning? The language matters

Woodcock on FDA’s accelerated approval and her next chapter

explore

3 questions for the future of Biden's cancer moonshot

A virus, fished out of a lake, may have saved a man’s life

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

A virus, fished out of a lake, may have saved a man’s life

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

focus

explore

entertainment

leisure time